Skip to NavigationSkip to content

Sanofi to axe 466 R&D positions in Germany and France

Published on 21/06/19 at 09:46am

Sanofi has announced that plans to reorganise its research and development operations will result in the losses of 466 jobs across Germany and France as part of a “voluntary departure programme”.

The French drugmaker revealed the move as it aims to downscale its development of cardiovascular drugs in favour of work in the areas of immuno-oncology, vaccines and rare disease. The firm said it would no longer pursue new development projects in the cardiovascular and diabetes space, instead focusing only on its existing research programmes.

The 466 cuts will be taken up voluntarily by willing staff members. Sanofi currently employs over 100,000 staff worldwide, with 15,000 installed in R&D functions.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches